Chester County News and Community Website
PLYMOUTH MEETING, PA — Braeburn announced that results from a National Institutes of Health-funded clinical trial evaluating a weekly extended-release buprenorphine treatment for opioid use disorder in pregnancy were published …
NIH-Funded Study Finds Weekly Buprenorphine Effective in Pregnancy Read More
WAYNE, PA — Aclaris Therapeutics, Inc. (Nasdaq: ACRS) will present new data from its Phase 2a trial of ATI-2138 in patients with moderate-to-severe atopic dermatitis at the 2026 American Academy …
Aclaris to Present Phase 2a ATI-2138 Data at Dermatology Meeting Read More
MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) has partnered with NeuroRPM to integrate an FDA-cleared artificial intelligence platform into its ongoing Parkinson’s disease study to improve symptom monitoring and …
Annovis Partners With NeuroRPM to Add AI Monitoring in PD Study Read More WAYNE, PA — Aclaris Therapeutics Inc. (Nasdaq: ACRS) has completed patient enrollment in its Phase 2 trial of bosakitug in patients with moderate-to-severe atopic dermatitis, marking a development milestone for …
Aclaris Completes Enrollment in Phase 2 Trial of Bosakitug for Atopic Dermatitis Read More
PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) announced it will host a business update webcast on Thursday, March 26, at 11:30 a.m. Eastern time, featuring Dr. Babar K. Rao, …
Medicus Pharma to Host Business Update Call Featuring Clinical Investigator Read More
WILMINGTON, DE — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) said it has received written confirmation from the U.S. Food and Drug Administration supporting a path toward approval of its depression treatment …
NRx Says FDA Will Review NRX-100 Without New Trials Read More
PLYMOUTH MEETING, PA — A nationwide clinical trial found that cancer patients who followed a structured exercise program during chemotherapy reported fewer problems with thinking and memory, according to research …
Study Finds Exercise May Reduce Cognitive Effects During Chemotherapy Read More
PHILADELPHIA, PA — Century Therapeutics Inc. (Nasdaq: IPSC) reported its financial results for 2025 and outlined progress across its pipeline of stem cell-derived therapies, including plans to submit a regulatory …
Century Therapeutics Reports 2025 Results, Advances Cell Therapy Pipeline Read More
PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) reported additional data from its Phase 2 SKNJCT-003 clinical study evaluating the SkinJect microneedle delivery system for the treatment of basal cell …
Medicus Reports Phase 2 Results for SkinJect Basal Cell Carcinoma Study Read More
HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) announced that the U.S. Food and Drug Administration has approved TECVAYLI (teclistamab-cqyv) in combination with DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) for adults …
FDA Approves TECVAYLI and DARZALEX FASPRO Combo for Multiple Myeloma Read More